Finding for B cell epitopes for E. coli E104:H4, a first step for vaccine development

How to cite this article:
Wiwanitkit V. Finding for B cell epitopes for E. coli E104:H4, a first step for vaccine development. Ann Trop Med Public Health 2012;5:407-8


How to cite this URL:
Wiwanitkit V. Finding for B cell epitopes for E. coli E104:H4, a first step for vaccine development. Ann Trop Med Public Health [serial online] 2012 [cited 2020 Aug 8];5:407-8. Available from:


The problem of pandemic E. coli E104:H4 infection has become a concern at the global level. Attempts to stop the outbreak and confine the infection in a limited area are the present aims. Basically, to fight the deadly E. coli infection, use of vaccine is the first priority. [1] Indeed, formulation of a new E. coli vaccine has been continuously performed over the years. The direct inoculation to find a vaccine model is used in some experiments, but it poses risk and can induce severe diarrhea in the experimented volunteer subject. [2] In addition, a long time has to be used in finding the proper composition for future vaccine development in a traditional way. Because of the nature of the outbreak, an interesting management concept is the production of new pandemic vaccines. This can be the tool for fighting the problem. Finding a new vaccine might have been difficult in the past; however, it becomes easier in the present day using the advent vaccinomics technology. Here, the author reports on the preliminary study on findings for B cell epitopes for E. coli E104:H4. The vaccinomics approach as previously published by the author’s laboratory is used. [3],[4] Briefly, the ABCpred Prediction Server [5] is used. The selected study protein is the WbwC (GenBank: AAK64375.1), which is a product of O104-specific genes. Based on the assessment, the determined epitopes include 84 NELIFRMDTDDICLPE and 77 HGLQYCRNELIFRMDT. These epitopes can be further used for manipulation to derive the new vaccine alternative for fighting the problem. Accompanied with the present advent in vaccine recombinant technology for E. coli vaccine development, [6] the new vaccine might be successfully developed based on this basic additional immunological information.



1. Panda A, Tatarov I, Melton-Celsa AR, Kolappaswamy K, Kriel EH, Petkov D, et alEscherichia coli O157: H7 infection in Dutch beted and New Zealand white rabbits. Comp Med 2010;60:31-7.
2. Harro C, Chakraborty S, Feller A, Denearing B, Cage A, Ram M, et al. Refinement of a Human Challenge Model for Evaluation of Enterotoxigenic E. coli (ETEC) Vaccines. Clin none Vaccine none Immunol 2011;18:1719-27.
3. Wiwanitkit V. Predicted B-cell epitopes on 18 kDa antigen of Haemophilus ducreyi. Indian J Dermatol Venereol Leprol 2008;74:676- 7.
4. Wiwanitkit V. Predicted B-cell epitopes of HER-2 oncoprotein by a bioinformatics method: A clue for breast cancer vaccine development. Asian Pac J Cancer Prev 2007;8:137-8.
5. Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins 2006;65:40-8.
6. Svennerholm AM. From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development. Indian J Med Res 2011;133:188-96.

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1755-6783.102096

Paul Mies has now been involved with test reports and comparing products for a decade. He is a highly sought-after specialist in these areas as well as in general health and nutrition advice. With this expertise and the team behind, they test, compare and report on all sought-after products on the Internet around the topics of health, slimming, beauty and more. The results are ultimately summarized and disclosed to readers.


Please enter your comment!
Please enter your name here